Abstract
Background Studying within-host genetic diversity of Mycobacterium tuberculosis (Mtb) in patients during treatment may identify adaptations to antibiotic and immune pressure.
Understanding the significance of genetic heteroresistance, and more specifically heterozygous resistance-associated variants (RAVs), is clinically important given increasing use of rapid molecular tests and whole genome sequencing (WGS).
Methods We analyse data from six cohort studies in KwaZulu-Natal, South Africa. Most patients (>75%) had baseline rifampicin-resistance. Sputum was collected for culture at baseline and at between two and nine intervals until month six. Positive cultures underwent WGS. Mixed infections and reinfections were excluded from analysis.
Findings Baseline Mtb genetic diversity was independently associated with cavitary disease, HIV coinfection and not taking antiretroviral therapy, infection with lineage 2 strains and absence of second-line drug resistance. Baseline genetic diversity was not associated with six-month outcome. Genetic diversity increased following treatment at week one and two before returning to baseline levels. Baseline genetic heteroresistance was most common for bedaquiline (6/10 [60%] of isolates with RAVs) and fluoroquinolones (9/62 [13%]). Most patients with heterozygous RAVs on WGS with sequential isolates available demonstrated persistence or fixation RAV(s) (17/20, 85%). New RAVs emerged in 9/286 (3%) patients during treatment. We could detect low-frequency RAVs preceding only preceded emergent resistance in only one case.
Interpretation In single-strain Mtb infections, pre-treatment within-host bacterial genetic diversity did not predict outcome but may reveal adaptations to host and drug pressures. Predicting emergent resistance from low-frequency RAVs requires further work to separate transient from consequential mutations.
Competing Interest Statement
Camus Nimmo and James Millard declare grants from the Wellcome Trust. Alexander S. Pym is now employed by Janssen Pharmaceutica. Max O’Donnell declares grants from NIH/NIAID. François Balloux declares grants from MRC, BBSRC and NIHR UCLH BRC.
Funding Statement
CN is supported by the Wellcome Trust (203583/Z/16/Z). JM is supported by the Wellcome Trust (203919/Z/16/Z). MO is supported by National Institutes of Health/National Institute of Allergy and Infectious Diseases (R01AI124413). FB acknowledges support from the Medical Research Council (MRC) (MR/P007597/1), the BBSRC (BB/R01356X/1) and the National Institute for Health Research University College London Hospitals Biomedical Research Centre. The funders did not have any role in study design, data collection, data analysis, interpretation, or writing of the report.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
c.nimmo.04{at}cantab.net
Data Availability
Anonymised identifiers for patients included in all analyses and corresponding NCBI SRA accessions are listed in the Supplementary Spreadsheet. All whole genome sequencing data are available under the NCBI SRA BioProject PRJNA559528.